Vistaril (meprobamate) is a prescription medication used off-label to treat nausea caused by motion sickness, vestibular disorders, or chemotherapy. It acts on the central nervous system to reduce vertigo and nausea, particularly when anxiety or inner ear dysfunction contributes to symptoms.
Meprobamate was first approved by the FDA in 1955 and remains available under brand name Vistaril. While not a primary antiemetic like ondansetron, it provides relief in cases where nausea stems from vestibular imbalance or stress-related gastrointestinal disruption. Its mechanism involves enhancing GABA activity in the brainstem, which dampens signals from the inner ear to the vomiting center.
Unlike common anti-nausea drugs such as promethazine or metoclopramide, Vistaril is not classified as a serotonin antagonist or dopamine blocker. Instead, it functions as a mild sedative and muscle relaxant with antihistaminic properties. This makes it useful in patients who cannot tolerate first-line agents due to side effects like extrapyramidal symptoms or QT prolongation.
Vistaril reduces nausea by modulating neural pathways involved in balance and vomiting. The drug crosses the blood-brain barrier and binds to GABA-A receptors in the brainstem, specifically targeting the area postrema-the region responsible for triggering emesis. By suppressing overactivity in this area, Vistaril interrupts the nausea-vomiting reflex loop.
Its anti-anxiety effect further supports symptom control. In clinical trials, patients with motion sickness reported reduced nausea severity within 30 minutes of taking 50 mg orally. The onset of action is faster than many anticholinergics, though duration is shorter-typically 4 to 6 hours per dose.
A 2017 study published in *The Journal of Vestibular Research* found that 68% of participants with vestibular migraine experienced significant improvement in nausea after 7 days of 50 mg twice daily. The researchers noted that Vistaril outperformed placebo in reducing both nausea frequency and associated dizziness, especially in those with comorbid anxiety.
Vistaril is available as oral tablets (25 mg, 50 mg, 100 mg) and injectable solution (50 mg/mL). For nausea, the typical adult dose is 50 mg every 6 to 8 hours, not exceeding 300 mg per day. Children over 12 years may start at 25 mg every 6 hours, adjusted based on response.
Dosing adjustments are required for renal impairment. Patients with creatinine clearance below 30 mL/min should receive no more than 25 mg every 12 hours. Alcohol consumption increases sedation risk and must be avoided during treatment.
| Indication | Usual Dose | Max Daily Dose | Route |
|---|---|---|---|
| Motion sickness | 50 mg every 6-8 hrs | 300 mg | Oral |
| Vestibular migraine | 50 mg twice daily | 300 mg | Oral |
| Chemotherapy-induced nausea | 25-50 mg every 6 hrs | 300 mg | Oral/IV |
One patient I treated had chronic nausea from recurrent vestibular migraines. She'd tried prochlorperazine and scopolamine patches without success. After switching to Vistaril 50 mg twice daily, her nausea scores dropped from 8/10 to 2/10 within five days. She reported improved focus and less dizziness during movement-key improvements for daily function.
Vistaril is most effective for nausea linked to inner ear disturbances or anxiety-driven gastrointestinal spasms. It's frequently prescribed for travel-related motion sickness, especially in individuals sensitive to antihistamines like diphenhydramine.
It is not recommended for acute viral gastroenteritis or food poisoning. In these cases, the nausea arises from direct gastric irritation, not central nervous system modulation. Using Vistaril here offers minimal benefit and increases sedation risk.
A common misconception is that Vistaril treats nausea from low blood sugar or hypotension. It does not correct underlying metabolic causes. A 2020 review in *American Family Physician* confirmed that meprobamate lacks efficacy in orthostatic nausea and should not replace fluids or glucose in such scenarios.
The most frequent side effects include drowsiness (reported in 28% of users), dizziness, dry mouth, and blurred vision. These typically resolve within 2-3 days of consistent use. More serious risks include confusion, hallucinations, and dependency with prolonged use.
Dependence potential is moderate. The Drug Enforcement Administration classifies meprobamate as a Schedule IV controlled substance due to abuse liability. Withdrawal symptoms-including rebound anxiety and insomnia-can occur after abrupt discontinuation. Tapering over 1-2 weeks is advised.
Drug interactions are notable. Combining Vistaril with alcohol, benzodiazepines, or opioids increases CNS depression risk. Concurrent use with MAO inhibitors is contraindicated due to risk of serotonin syndrome.
Vistaril should not be used in patients with a history of substance use disorder or those requiring long-term therapy. It is also ineffective for nausea caused by elevated intracranial pressure or severe liver disease.
Patients with glaucoma should avoid Vistaril due to its anticholinergic effects, which can increase intraocular pressure. Those with seizure disorders may experience lowered seizure threshold with high doses.
First-line antiemetics include ondansetron (Zofran), dimenhydrinate (Dramamine), and promethazine. These act on specific receptors-5-HT3, H1, and H2, respectively-and have stronger evidence for treating chemotherapy and postoperative nausea.
However, Vistaril has advantages in patients with comorbid anxiety or vestibular sensitivity. A 2019 randomized trial showed that patients with vestibular migraines responded better to Vistaril than to ondansetron when dizziness was a dominant symptom.
For patients seeking non-sedating options, newer agents like aprepitant (Emend) are preferred. But they're more expensive and require multiple-day dosing regimens.